EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access

Efficacy and Safety of Bimagrumab in Adults With Obesity and Metabolic Dysfunction: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Chuhan Shao iD, Hanmo Lin iD, Jie Yu iD, Haiyan Chen, Yaolin Ren iD, Jing Ren, Yuan Zeng iD, Yifan Wu, Qian Zhang, Xinhua Xiao iD

Diabetes, Obesity and Metabolism · 2026-10 · 28 (10) · 9433-9442

DOI: 10.1111/dom.71156 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 30.07.2026. Verfasst von Chuhan Shao und 9 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Endocrinology (Peking Union Medical College Hospital), Diabetes Research Center of Chinese Academy of Medical Sciences, Departm…. Hauptthemen laut MEDLINE: Obesity, Antibodies, Monoclonal, Humanized, Diabetes Mellitus, Type 2, Metabolic Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CAMS Innovation Fund for Medical Sciences, National Natural Science Foundation of China, The Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This study aims to systematically evaluate the efficacy of bimagrumab on body composition and glucose parameters in adults with obesity and metabolic dysfunction and its safety profile.

Methods

We searched MEDLINE, PubMed, Embase, and the Cochrane Library on April 20, 2026, for randomized controlled trials (RCTs) assessing bimagrumab treatment in adults with obesity, insulin resistance, or type 2 diabetes mellitus (T2DM). The risk of bias was assessed using the Cochrane Risk of Bias tool (RoB 2), and meta‐analyses of efficacy and safety data were conducted using R software. The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) system was used to assess the strength of evidence. The study was registered with PROSPERO (CRD420261377110).

Results

Of the 134 retrieved records, 4 RCTs (enrolling 268 participants) were included. The included population represented a broad spectrum of metabolic dysfunction, from obesity and nondiabetic insulin resistance to established T2DM. Compared with placebo, bimagrumab treatment significantly reduced total weight (mean difference [MD] –4.85 kg, 95% confidence interval [CI] –6.82 to −2.88), fat mass (−4.72 kg [−8.05 to −1.40]), and glycated haemoglobin (HbA1c) (−0.13% [−0.23 to −0.03]) and significantly increased total lean mass (1.66 kg [0.81 to 2.51]). However, bimagrumab led to an increase in low‐density lipoprotein (LDL) concentrations of 0.47 mmol/L [0.03 to 0.91] and significantly increased incidences of discontinuation (risk ratio [RR] 5.75 [1.61 to 20.46]), muscle spasms (RR 10.44 [4.23 to 25.75]), and diarrhoea (RR 4.91 [2.38 to 10.11]).

Conclusion

Bimagrumab effectively reversed adverse effects on body composition in obese individuals, resulting in significant fat reduction, increased skeletal muscle mass, and improved glycemic control, suggesting that bimagrumab is a promising new target for personalized metabolic therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityAntibodies, Monoclonal, HumanizedDiabetes Mellitus, Type 2Metabolic DiseasesHumansRandomized Controlled Trials as TopicInsulin ResistanceAdultBody CompositionTreatment OutcomeBlood Glucose

Stichwörter der Autor:innen

antiobesity drugmeta‐analysisobesity therapyrandomized trialtype 2 diabetes

Substanzen

Antibodies, Monoclonal, HumanizedbimagrumabBlood Glucose

Autor:innen und Institutionen

  • NHC Key Laboratory of Endocrinology (Peking Union Medical College Hospital), Diabetes Research Center of Chinese Academy of Medical Sciences, Department of Endocrinology, Peking Union Medical College Hospital, Chinese A…

ORCID-Profile: Chuhan Shao, Hanmo Lin, Jie Yu, Yaolin Ren, Yuan Zeng, Xinhua Xiao

Förderung

  • CAMS Innovation Fund for Medical Sciences
  • National Natural Science Foundation of China
  • The Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences
  • National High Level Hospital Clinical Research Funding
  • Capital's Funds for Health Improvement and Research
  • Science and Technology Research Project of China Science and Technology Development Center for Chinese Medicine
  • Beijing Municipal Science & Technology Commission
  • Beijing Natural Science Foundation

Zitieren

APA

Shao, C., Lin, H., Yu, J., Chen, H., Ren, Y., Ren, J., Zeng, Y., Wu, Y., Zhang, Q., & Xiao, X. (2026). Efficacy and Safety of Bimagrumab in Adults With Obesity and Metabolic Dysfunction: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Diabetes, Obesity and Metabolism, 28(10), 9433-9442. https://doi.org/10.1111/dom.71156

Vancouver

Shao C, Lin H, Yu J, Chen H, Ren Y, Ren J, et al. Efficacy and Safety of Bimagrumab in Adults With Obesity and Metabolic Dysfunction: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Diabetes, Obesity and Metabolism. 2026;28(10):9433-9442. doi:10.1111/dom.71156

BibTeX
@article{Shao2026,
  author = {Shao, Chuhan and Lin, Hanmo and Yu, Jie and Chen, Haiyan and Ren, Yaolin and Ren, Jing and Zeng, Yuan and Wu, Yifan and Zhang, Qian and Xiao, Xinhua},
  title = {Efficacy and Safety of Bimagrumab in Adults With Obesity and Metabolic Dysfunction: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {10},
  pages = {9433--9442},
  doi = {10.1111/dom.71156}
}
Kostenlos starten →